candesartan has been researched along with simvastatin in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, JA | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, J | 1 |
| Biesenbach, P; Gremmel, T; Hörl, WH; Kain, R; Säemann, MD | 1 |
| Damen, CW; González, O; Hankemeier, T; van der Kloet, FM; van Vliet, M; Vreeken, RJ | 1 |
| Flegal, JM; Mote, PL; Spindler, SR | 1 |
1 review(s) available for candesartan and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
9 other study(ies) available for candesartan and simvastatin
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Family Practice; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Losartan; Male; Middle Aged; Patient Satisfaction; Pyrroles; Simvastatin; Tetrazoles; Treatment Outcome | 2007 |
Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cholesterol; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Losartan; Male; Pyrroles; Retrospective Studies; Simvastatin; Tetrazoles; Therapeutic Equivalency; Treatment Outcome | 2008 |
Gross proteinuria and subacute renal failure after coronary angiography - a case report of cholesterol crystal embolization.
Topics: Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; Austria; Benzimidazoles; Biopsy; Biphenyl Compounds; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Angiography; Coronary Artery Disease; Disease Progression; Embolism, Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Malignant; Kidney; Male; Middle Aged; Proteinuria; Simvastatin; Tetrazoles | 2010 |
Matrix Effect Compensation in Small-Molecule Profiling for an LC-TOF Platform Using Multicomponent Postcolumn Infusion.
Topics: Acetaminophen; Benzimidazoles; Benzoates; Biphenyl Compounds; Chromatography, High Pressure Liquid; Clomipramine; Dihydropyridines; Enkephalin, Leucine; Humans; Mass Spectrometry; Nifedipine; Pharmaceutical Preparations; Simvastatin; Telmisartan; Tetrazoles; Time Factors | 2015 |
Combined statin and angiotensin-converting enzyme (ACE) inhibitor treatment increases the lifespan of long-lived F1 male mice.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Cholesterol; Chromatography, Liquid; Cohort Studies; Drug Synergism; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Longevity; Male; Mice; Mice, Inbred C57BL; Ramipril; Simvastatin; Tandem Mass Spectrometry; Tetrazoles; Triglycerides | 2016 |